Уважаемые пользователи!
Мы рады представить вам новую версию сайта с улучшенным интерфейсом и новыми возможностями.
Приглашаем вас ознакомиться и поделиться обратной связью. Спасибо, что вы с нами!
Попробовать!

OCT STEMI: Optical Coherence Tomography Guidance During Primary PCI in AMI

15.09.20141822
The OCT STEMI trial presented Sept. 14 at TCT 2014 looked at optical coherence tomography (OCT) guidance during drug-eluting stent implantation in patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).

Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment

12.09.20141804
What is the relationship between worsening renal failure (WRF) and outcomes in heart failure patients with preserved ejection fraction (HFpEF), and the interaction with renin-angiotensin-aldosterone system (RAAS) blockade?

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study

11.09.20142081
The role of statins in the development of microvascular disease in patients with diabetes is unknown.

Analysis of resting heart rate and clinical characteristics in outpatients with stable coronary artery disease in Turkey: PULSE study

10.09.20141586
An association between resting heart rate (RHR) and cardiovascular morbidity and mortality has been shown in patients with coronary artery disease (CAD).

FDA grants clearance for mobile AF detection algorithm

09.09.20141741
AliveCor Inc. announced that it has received clearance from the FDA for an algorithm designed to detect atrial fibrillation using a mobile device.

New ESC Guidelines on pulmonary embolism

08.09.20142589
ESC Guidelines on the management of patients with pulmonary embolism (PE) have been released during this congress and provide clinicians with a user-friendly summary of current evidence in the field.

Potent Statin Offers No Help After Cardiac Surgery

05.09.20141740
The powerful lipid-lowering drug rosuvastatin (Crestor) -- also purported to be an effective anti-inflammatory agent -- was powerless to prevent postoperative cardiac surgery complications such as atrial fibrillation in a randomized trial reported here.
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.